GenFleet Therapeutics is a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, founded in 2017 by veteran drug developers with the support from top-tier venture capital investors. Dedicated to serving significant unmet medical needs, GenFleet constructs its R&D platform on the basis of disease biology and translational medicine, and researches into latest biological mechanism of cancer pathways, tumor microenvironment and human immunoregulation. GenFleet's rich and diversified pipeline highlights multiple first-in-class products with novel mechanisms and global intellectual property rights.
Staff with Master or Doctoral Degrees
Through years of endeavor, GenFleet has set up industry-leading capabilities and expertise in developing novel drugs - both small molecules and biologics. Its cutting-edge pipeline includes over 10 products, many of which have progressed into clinical stages.
Among them, the TGF-β R1 (transforming growth factor-β receptor 1) inhibitor is entering phase II clinical trial and boasts broad prospects of treating various solid tumors; the CDK9（cyclin-dependent kinase 9） inhibitor has been granted with IND approval in China and US, marking the beginning of the company's global multi-center clinical trial strategy；besides, GenFleet is the first Chinese company that moves RIPK1 inhibitor development into clinical stage.
May 10，2021 (Tianjin, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced that the first patient has been dosed in its first-in-human trial of GFH009.
April 27, 2021 (Melbourne, Australia) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced its first-in-human phase I trial of GFH312 has achieved dosing of subjects in the first cohort.